Variability in Estrogen-Metabolizing Genes and Their Association with Genomic Instability in Untreated Breast Cancer Patients and Healthy Women

Table 2

The genotype frequencies of the CYP17, CYP1B1, CYP1A1, and COMT gene variants in breast cancer patients and controls, and after menopause.

Genotype	Breast cancer patients (𝑛=62)		Controls (𝑛=62)		OR (95% CI)	P value
	Number	Frequency	Number	Frequency
CYP17
Premenopause
TT	16	0.25	22	0.35	1.0 (reference)	.81
TC+CC	14	0.23	17	0.27	1.1 (0.4-2.9)
Postmenopause
TT	11	0.18	16	0.26	1.0 (reference)	.01
TC+CC	21	0.34	7	0.12	4.3 (1.3–13.7)
CYP1B1
Premenopause
Val/Val	6	0.1	15	0.24	1.0 (reference)	.11
Val/Leu+Leu/Leu	24	0.39	24	0.39	2.5 (0.8–7.5)
Postmenopause
Val/Val	11	0.18	6	0.1	1.0 (reference)	.56
Val/Leu+Leu/Leu	21	0.33	17	0.27	0.6 (0.2–2.1)
CYP1A1
Premenopause
TT	16	0.25	36	0.58	1.0 (reference)	.0004
TC+CC	14	0.23	3	0.05	10.5 (2.6–41.7)
Postmenopause
TT	24	0.39	17	0.27	1.0 (reference)	1.0
TC+CC	8	0.13	6	0.1	0.9 (0.2–3.2)
COMT
Premenopause
Val/Val	10	0.16	24	0.38	1.0 (reference)	.02
Val/Met+Met/Met	20	0.32	15	0.24	3.2 (1.1–8.6)
Postmenopause
Val/Val	11	0.18	12	0.2	1.0 (reference)	.2
Val/Met+Met/Met	21	0.34	11	0.18	2.0 (0.6–6.2)